GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference

News
Article

Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.

While manual segmentation of lesions and comparisons of PET and SPECT images would take hours to ascertain whole-body tumor burden, an emerging artificial intelligence (AI)-enabled software may provide significantly enhanced diagnostic efficiency.

The updated LesionID Pro software, which will be introduced by GE HealthCare at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, features automated zero-click pre-processing of PET and SPECT images.

GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference

Powered by enhanced AI algorithms and designed with input from leading theranostics clinicians, the new LesionID Pro software, which reportedly offers automated analysis of whole-body tumor burden, is slated to be introduced at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference. (Image courtesy of GE HealthCare.)

Powered by enhanced AI algorithms and designed with input from leading theranostics clinicians, the new LesionID Pro offers automated analysis of whole-body tumor burden, according to GE HealthCare and MIM Software, the developers of LesionID Pro.

“We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient’s entire care journey – from the imaging equipment needed for a noninvasive look at a patient’s anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes,” noted Jean-Luc Procaccini, the president and CEO of molecular Imaging and computed tomography at GE HealthCare.

GE HealthCare noted that LesionID Pro with automated pre-click processing is pending 510(k) clearance by the Food and Drug Administration (FDA).

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Related Content
© 2025 MJH Life Sciences

All rights reserved.